Tags

Type your tag names separated by a space and hit enter

Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort.
Mov Disord. 2020 02; 35(2):279-287.MD

Abstract

BACKGROUND

Predicting prognosis in Parkinson's disease (PD) has important implications for individual prognostication and clinical trials design and targeting novel treatments. Blood biomarkers could help in this endeavor.

METHODS

We identified 4 blood biomarkers that might predict prognosis: apolipoprotein A1, C-reactive protein, uric acid and vitamin D. These biomarkers were measured in baseline serum from 624 Parkinson's disease subjects (median disease duration, 1.0 years; interquartile range, 0.5-2.0) from the Oxford Discovery prospective cohort. We compared these biomarkers against PD subtypes derived from clinical features in the baseline cohort using data-driven approaches. We used multilevel models with MDS-UPDRS parts I, II, and III and Montreal Cognitive Assessment as outcomes to test whether the biomarkers predicted subsequent progression in motor and nonmotor domains. We compared the biomarkers against age of PD onset and age at diagnosis. The q value, a false-discovery rate alternative to P values, was calculated as an adjustment for multiple comparisons.

RESULTS

Apolipoprotein A1 and C-reactive protein levels differed across our PD subtypes, with severe motor disease phenotype, poor psychological well-being, and poor sleep subtype having reduced apolipoprotein A1 and higher C-reactive protein levels. Reduced apolipoprotein A1, higher C-reactive protein, and reduced vitamin D were associated with worse baseline activities of daily living (MDS-UPDRS II).

CONCLUSION

Baseline clinical subtyping identified a pro-inflammatory biomarker profile significantly associated with a severe motor/nonmotor disease phenotype, lending biological validity to subtyping approaches. No blood biomarker predicted motor or nonmotor prognosis. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Authors+Show Affiliations

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.Nuffield Department of Clinical Neurosciences, Division of Clinical Neurology, University of Oxford, Oxford, UK. Oxford Parkinson's Disease Centre, University of Oxford, Oxford, UK.Department of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.Department of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.Nuffield Department of Clinical Neurosciences, Division of Clinical Neurology, University of Oxford, Oxford, UK. Oxford Parkinson's Disease Centre, University of Oxford, Oxford, UK.Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.Nuffield Department of Clinical Neurosciences, Division of Clinical Neurology, University of Oxford, Oxford, UK. Oxford Parkinson's Disease Centre, University of Oxford, Oxford, UK. Department of Clinical Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

31693246

Citation

Lawton, Michael, et al. "Blood Biomarkers With Parkinson's Disease Clusters and Prognosis: the Oxford Discovery Cohort." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 35, no. 2, 2020, pp. 279-287.
Lawton M, Baig F, Toulson G, et al. Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort. Mov Disord. 2020;35(2):279-287.
Lawton, M., Baig, F., Toulson, G., Morovat, A., Evetts, S. G., Ben-Shlomo, Y., & Hu, M. T. (2020). Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort. Movement Disorders : Official Journal of the Movement Disorder Society, 35(2), 279-287. https://doi.org/10.1002/mds.27888
Lawton M, et al. Blood Biomarkers With Parkinson's Disease Clusters and Prognosis: the Oxford Discovery Cohort. Mov Disord. 2020;35(2):279-287. PubMed PMID: 31693246.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort. AU - Lawton,Michael, AU - Baig,Fahd, AU - Toulson,Greg, AU - Morovat,Alireza, AU - Evetts,Samuel G, AU - Ben-Shlomo,Yoav, AU - Hu,Michele T, Y1 - 2019/11/06/ PY - 2019/02/26/received PY - 2019/09/03/revised PY - 2019/09/18/accepted PY - 2019/11/7/pubmed PY - 2021/1/16/medline PY - 2019/11/7/entrez KW - Parkinson's disease KW - blood biomarkers KW - cohort studies KW - prognosis SP - 279 EP - 287 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 35 IS - 2 N2 - BACKGROUND: Predicting prognosis in Parkinson's disease (PD) has important implications for individual prognostication and clinical trials design and targeting novel treatments. Blood biomarkers could help in this endeavor. METHODS: We identified 4 blood biomarkers that might predict prognosis: apolipoprotein A1, C-reactive protein, uric acid and vitamin D. These biomarkers were measured in baseline serum from 624 Parkinson's disease subjects (median disease duration, 1.0 years; interquartile range, 0.5-2.0) from the Oxford Discovery prospective cohort. We compared these biomarkers against PD subtypes derived from clinical features in the baseline cohort using data-driven approaches. We used multilevel models with MDS-UPDRS parts I, II, and III and Montreal Cognitive Assessment as outcomes to test whether the biomarkers predicted subsequent progression in motor and nonmotor domains. We compared the biomarkers against age of PD onset and age at diagnosis. The q value, a false-discovery rate alternative to P values, was calculated as an adjustment for multiple comparisons. RESULTS: Apolipoprotein A1 and C-reactive protein levels differed across our PD subtypes, with severe motor disease phenotype, poor psychological well-being, and poor sleep subtype having reduced apolipoprotein A1 and higher C-reactive protein levels. Reduced apolipoprotein A1, higher C-reactive protein, and reduced vitamin D were associated with worse baseline activities of daily living (MDS-UPDRS II). CONCLUSION: Baseline clinical subtyping identified a pro-inflammatory biomarker profile significantly associated with a severe motor/nonmotor disease phenotype, lending biological validity to subtyping approaches. No blood biomarker predicted motor or nonmotor prognosis. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. SN - 1531-8257 UR - https://www.unboundmedicine.com/medline/citation/31693246/Blood_biomarkers_with_Parkinson's_disease_clusters_and_prognosis:_The_oxford_discovery_cohort_ L2 - https://doi.org/10.1002/mds.27888 DB - PRIME DP - Unbound Medicine ER -